191 related articles for article (PubMed ID: 27742673)
1. Efficacy of Adoptive T-cell Therapy Is Improved by Treatment with the Antioxidant N-Acetyl Cysteine, Which Limits Activation-Induced T-cell Death.
Scheffel MJ; Scurti G; Simms P; Garrett-Mayer E; Mehrotra S; Nishimura MI; Voelkel-Johnson C
Cancer Res; 2016 Oct; 76(20):6006-6016. PubMed ID: 27742673
[TBL] [Abstract][Full Text] [Related]
2. N-acetyl cysteine protects anti-melanoma cytotoxic T cells from exhaustion induced by rapid expansion via the downmodulation of Foxo1 in an Akt-dependent manner.
Scheffel MJ; Scurti G; Wyatt MM; Garrett-Mayer E; Paulos CM; Nishimura MI; Voelkel-Johnson C
Cancer Immunol Immunother; 2018 Apr; 67(4):691-702. PubMed ID: 29396710
[TBL] [Abstract][Full Text] [Related]
3. Activation induced cell death (AICD) of human melanoma antigen-specific TCR engineered CD8 T cells involves JNK, Bim and p53.
Chhabra A; Mukherji B; Batra D
Expert Opin Ther Targets; 2017 Feb; 21(2):117-129. PubMed ID: 27935327
[TBL] [Abstract][Full Text] [Related]
4. Failed adoptive immunotherapy with tumor-specific T cells: reversal with low-dose interleukin 15 but not low-dose interleukin 2.
Roychowdhury S; May KF; Tzou KS; Lin T; Bhatt D; Freud AG; Guimond M; Ferketich AK; Liu Y; Caligiuri MA
Cancer Res; 2004 Nov; 64(21):8062-7. PubMed ID: 15520217
[TBL] [Abstract][Full Text] [Related]
5. Adoptive transfer of in vitro-targeted, activated T lymphocytes results in total tumor regression.
Altenschmidt U; Klundt E; Groner B
J Immunol; 1997 Dec; 159(11):5509-15. PubMed ID: 9548491
[TBL] [Abstract][Full Text] [Related]
6. Permissive expansion and homing of adoptively transferred T cells in tumor-bearing hosts.
Perez C; Jukica A; Listopad JJ; Anders K; Kühl AA; Loddenkemper C; Blankenstein T; Charo J
Int J Cancer; 2015 Jul; 137(2):359-71. PubMed ID: 25530110
[TBL] [Abstract][Full Text] [Related]
7. In vivo programming of tumor antigen-specific T lymphocytes from pluripotent stem cells to promote cancer immunosurveillance.
Lei F; Zhao B; Haque R; Xiong X; Budgeon L; Christensen ND; Wu Y; Song J
Cancer Res; 2011 Jul; 71(14):4742-7. PubMed ID: 21628492
[TBL] [Abstract][Full Text] [Related]
8. Fate and function of anti-CD3/CD28-activated T cells following adoptive transfer: IL-2 promotes development of anti-tumor memory T cells in vivo.
Hughes DP; Baskar D; Urban FF; Friedman MS; Braun TM; McDonagh KT
Cytotherapy; 2005; 7(5):396-407. PubMed ID: 16236629
[TBL] [Abstract][Full Text] [Related]
9. Generation of anti-tumour effector T cells from naïve T cells by stimulation with dendritic/tumour fusion cells.
Ishida A; Tanaka H; Hiura T; Miura S; Watanabe S; Matsuyama K; Kuriyama H; Tanaka J; Kagamu H; Gejyo F; Yoshizawa H
Scand J Immunol; 2007 Nov; 66(5):546-54. PubMed ID: 17953530
[TBL] [Abstract][Full Text] [Related]
10. The optimal interval for dendritic cell vaccination following adoptive T cell transfer is important for boosting potent anti-tumor immunity.
Park MY; Kim CH; Sohn HJ; Oh ST; Kim SG; Kim TG
Vaccine; 2007 Oct; 25(42):7322-30. PubMed ID: 17889413
[TBL] [Abstract][Full Text] [Related]
11. Treatment of intracranial tumors by systemic transfer of superantigen-activated tumor-draining lymph node T cells.
Inoue M; Plautz GE; Shu S
Cancer Res; 1996 Oct; 56(20):4702-8. PubMed ID: 8840987
[TBL] [Abstract][Full Text] [Related]
12. T-cell receptor gene therapy in human melanoma-bearing immune-deficient mice: human but not mouse T cells recapitulate outcome of clinical studies.
Straetemans T; Coccoris M; Berrevoets C; Treffers-Westerlaken E; Scholten CE; Schipper D; Ten Hagen TL; Debets R
Hum Gene Ther; 2012 Feb; 23(2):187-201. PubMed ID: 21958294
[TBL] [Abstract][Full Text] [Related]
13. Blockade of Programmed Death 1 Augments the Ability of Human T Cells Engineered to Target NY-ESO-1 to Control Tumor Growth after Adoptive Transfer.
Moon EK; Ranganathan R; Eruslanov E; Kim S; Newick K; O'Brien S; Lo A; Liu X; Zhao Y; Albelda SM
Clin Cancer Res; 2016 Jan; 22(2):436-47. PubMed ID: 26324743
[TBL] [Abstract][Full Text] [Related]
14. Human melanoma immunotherapy using tumor antigen-specific T cells generated in humanized mice.
Hu Z; Xia J; Fan W; Wargo J; Yang YG
Oncotarget; 2016 Feb; 7(6):6448-59. PubMed ID: 26824989
[TBL] [Abstract][Full Text] [Related]
15. Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice.
Proietti E; Greco G; Garrone B; Baccarini S; Mauri C; Venditti M; Carlei D; Belardelli F
J Clin Invest; 1998 Jan; 101(2):429-41. PubMed ID: 9435316
[TBL] [Abstract][Full Text] [Related]
16. Lack of p53 Augments Antitumor Functions in Cytolytic T Cells.
Banerjee A; Thyagarajan K; Chatterjee S; Chakraborty P; Kesarwani P; Soloshchenko M; Al-Hommrani M; Andrijauskaite K; Moxley K; Janakiraman H; Scheffel MJ; Helke K; Armenson K; Palanisamy V; Rubinstein MP; Mayer EG; Cole DJ; Paulos CM; Christina-Voelkel-Johnson ; Nishimura MI; Mehrotra S
Cancer Res; 2016 Sep; 76(18):5229-5240. PubMed ID: 27466285
[TBL] [Abstract][Full Text] [Related]
17. Lack of specific gamma-retroviral vector long terminal repeat promoter silencing in patients receiving genetically engineered lymphocytes and activation upon lymphocyte restimulation.
Burns WR; Zheng Z; Rosenberg SA; Morgan RA
Blood; 2009 Oct; 114(14):2888-99. PubMed ID: 19589923
[TBL] [Abstract][Full Text] [Related]
18. Delivery of CCL21 to metastatic disease improves the efficacy of adoptive T-cell therapy.
Thanarajasingam U; Sanz L; Diaz R; Qiao J; Sanchez-Perez L; Kottke T; Thompson J; Chester J; Vile RG
Cancer Res; 2007 Jan; 67(1):300-8. PubMed ID: 17210711
[TBL] [Abstract][Full Text] [Related]
19. Rebuilding human leukocyte antigen class II-restricted minor histocompatibility antigen specificity in recall antigen-specific T cells by adoptive T cell receptor transfer: implications for adoptive immunotherapy.
Spaapen R; van den Oudenalder K; Ivanov R; Bloem A; Lokhorst H; Mutis T
Clin Cancer Res; 2007 Jul; 13(13):4009-15. PubMed ID: 17606735
[TBL] [Abstract][Full Text] [Related]
20. Alkylating agent melphalan augments the efficacy of adoptive immunotherapy using tumor-specific CD4+ T cells.
Lu X; Ding ZC; Cao Y; Liu C; Habtetsion T; Yu M; Lemos H; Salman H; Xu H; Mellor AL; Zhou G
J Immunol; 2015 Feb; 194(4):2011-21. PubMed ID: 25560408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
